2 billion heavyweight varieties of generic spout intensive listing patent cliff also need what supporting perfection?

Giafitini originally studied Aslea, listed in 2005 in China, the price of 5000 yuan / box, AstraZeneca through the national negotiations, the price from 5000 yuan to 2358 yuan, a reduction of more than two-thirds.
in the first round of tape procurement, AstraZeneca became the rare winning bid of the original pharmaceutical company, with a price of 547 yuan.
was selected by Qilu, Zhengda Tianqing and AstraZeneca for 257 yuan, 450 yuan and 547 yuan (10 pieces/25mg) respectively in the 4-plus-seven expansion in September 2019.
in 2019, china's public hospital terminals, jifiedini sales of 2.18 billion, down 7.51% from 2018.
the 2019 market share of the breed, AstraZeneca fell to 74.96 percent, Zilu Pharmaceuticals grew to 23.56 percent, and Zhengtian also quickly won 1.48 percent.
the largest variable of the variety is national collection.
the second round of national collection and expansion, the agreed procurement volume for the first year agreed to purchase the calculation of 70% of the base, in order of selected provinces, roughly equal.
the next year agreed to purchase quantity in principle not less than the first year of the selected variety agreed to purchase volume.
, Jiangxi Province issued a briefing on the implementation of the state-organized centralized procurement of drugs and the use of the pilot expansion.
the lowest completion rate for Giafitini was 23.21 per cent. in addition to the five generic drugs that have been evaluated (or treated as high) by Qilu, Zhengda Tianqing, Hunan Collum, Heng Rui, YangZijiang,
, there are also seven generic drugs from Nanjing Yuke, Tianshili, Shanghai Genesis, Suzhou Teri and other enterprises, including NATCO PharmaceuticalS imported generics.
" as the first collection of varieties, Gifitini has been the focus of attention.
in Jiangxi Province recently issued the implementation of the state-organized drug centralized procurement and use of the pilot expansion of the work of the briefing, its completion rate of the lowest, only 23.21%, but also caused industry concern.
the market pattern is bound to make waves again after the listing of competing products.
and from the next competitive market of this variety, about the original research drug patent cliff problem, there may be some supporting needs to be perfected.
to speed up the introduction of good efficacy, the amount of the original research drug listed in the domestic market, the price fell two times, a five-fold discount, a fold, this only held 75% of the market share.
in fact, the gyfietinib original research drug in the 4 plus 7 expansion of the circumference did not drop again, before dive to 547 yuan is a real drug economics measurement results.
two ideas: do not look at the collection market, the price of the original jifiedni even rebounded to 647 yuan, 747 yuan, even if twice as expensive as generic drugs or even more, in a few hundred yuan a box of the case, in the patient's drug astickness is still attractive.
again look at the collection market, the chinese price of the original research drug jified the highest price of generic drug competitors.
we should be grateful to any of the original drugs that have good efficacy and safety.
because there are chickens first, then eggs, first there are front waves, then there are waves.
the original research drug market, competition, collection of quotations, on the one hand, make generic drugs have the power to catch up, self-discipline in the price strategy, open;
planned to speed up the introduction of the original research drug, listing, will expand the industry's market vision.
the curve of comprehensive use of policies, industries and market means to stimulate, affect its price changes and sales volume into orbit after the original research drug was listed.
concerned about all the collection and not in-the-collection of the same-time generic drugs before the landing has excellent, just into the eyes of investors, drug regulatory reviewers, state-run decision-makers and other original research drugs, after which there are determined to compete with Taiwan, the conditions mature can enter the collection or with the collection of remote lysis.
before the large market sales, after the collection platform, collection inside and outside are two channels.
especially in addition to the collection, those involved in the collection of the failure, or varieties are not in the collection range of generic drugs, sales are not easy.
on the one hand, similar categories of indications drug space, is inevitably crowded by the selection of drugs;
specifically, there are three questions to explore: First, medical insurance is not collected, hospitals and not picked or insufficient procurement of some generic drugs to do hospital promotion difficult, can we encourage social pharmacies to voluntarily form a coalition with single collection, prescription outflow; So many patients who just need to take drugs, in doing drug economics analysis, how to and professional and the masses look forward to convergence;
generics are also patients' vitality, and require fireworks.
distinguish the status of drugs with efficacy and abnormally high prices In the field of chemical drugs, biological drugs, traditional Chinese medicine, a drug has efficacy, said that a drug has efficacy, there are many.
in the overall promotion of centralized procurement of drugs, three medical joint cage for birds today, we are more concerned about which new drugs, although not against the medical profession, the press aura, but wearing a high-priced, exclusive efficacy to be assessed high-footed cap.
these drugs are really packaged with heavy-duty products by the drug companies involved, and the prices are often at odds with the general principles and definitions of pharmaceutical economics.
is worth watching.
market prices with this attribute, including original research drugs, generics and some traditional Chinese medicines, innovative drugs, and even in a combination of medicines.
also includes: doctor-approved and recommended prescriptions, complementary treatment methods and comprehensive services.
can obviously see: on the one hand is the gifititini as the representative of the collection of drugs to reduce prices, but clinical sales are still not hot, as if the drug price reduction does not directly mean the increase in the use of drugs;
, we suggest: under the linkage of clinical diagnosis and treatment, medical insurance collection, the market supervision department as soon as possible to start the drug collection identity and classification labeling system.
on the one hand, makes the varieties and drugs that are included in the normal collection have a clear identity comparison, on the other hand, the collection and market bidding outside the impact of expensive drugs to make classification marks.
Always keep an eye on all available ones.、,、。
original title: from 2 billion heavy-duty varieties of generic drugs intensive listing, to see the patent cliff also need what supporting perfection?